Latest news with #USOTC
Malaysian Reserve
17-06-2025
- Health
- Malaysian Reserve
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patien
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo ANDEMBRY approval expands CSL's HAE franchise and underscores the company's legacy of delivering transformational innovations to the HAE community for over four decades KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) approved ANDEMBRY® (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. By targeting factor XIIa, a plasma protein that plays a key role in attacks of swelling in people with HAE, ANDEMBRY inhibits the top of the HAE cascade to prevent HAE attacks. ANDEMBRY, the only treatment to offer once-monthly dosing from the start for all patients, is a subcutaneous self-injection delivered in 15 seconds or less via an autoinjector with a citrate-free formula. HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. HAE occurs in about 1 in 50,000 people of any ethnic group. 'ANDEMBRY, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method,' said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. 'ANDEMBRY underscores our long-standing and enduring commitment to better the lives of the patients we serve, including those suffering with HAE. I'd like to thank all the physicians, patients and my colleagues who contributed to this exciting milestone for HAE patients and CSL.' The approval is supported by data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY: Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period. Reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo. Achieved more than 99 percent median reduction and an 88 percent mean reduction in HAE attacks requiring on-demand therapy, compared to placebo. Attained more than 99 percent median reduction and a 90 percent mean reduction in moderate or severe attacks, compared to placebo. The most common adverse reactions in the pivotal trial (incidence ≥7%) are nasopharyngitis and abdominal pain. A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. In the pivotal trial and the open-label extension study, injection-site reactions (e.g., injection-site bruising, injection-site erythema, injection-site hematoma, injection-site pruritus, injection-site urticaria) were reported in 23 (14%) patients. 'We've made significant progress in treating hereditary angioedema, yet many patients still experience painful and sometimes life-threatening HAE attacks and require frequent injections to manage them,' said Dr. Tim Craig, Professor of Medicine, Pediatrics and Biomedical Sciences at Penn State University. 'We now have a new option to manage this condition through a new target, as it allows us for the first time to inhibit the top of the HAE cascade by targeting factor XIIa.' 'ANDEMBRY, a novel once-monthly subcutaneous treatment that inhibits factor XIIa, is a welcome addition to the HAE treatment landscape,' said Anthony J. Castaldo, CEO and Chairman of the Board, US HAE Association and HAE International. 'People with HAE now have another choice for lessening the burden associated with this lifelong condition and realizing the community's shared goal of experiencing life to the fullest.' This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdon (UK), the European Union (EU), Japan, Switzerland, and United Arab Emirates. CSL Behring will launch ANDEMBRY commercially immediately, with availability before the end of June. Healthcare professionals and patients interested in learning more about ANDEMBRY or accessing the therapy are encouraged to utilize ANDEMBRY ConnectSM, designed to offer comprehensive support and assistance through various programs. For more information, call 844-423-4273 or visit About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death. About ANDEMBRYANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a new type of once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain FDA approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators. About the VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, an investigational first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing. The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks. IMPORTANT SAFETY INFORMATION What is ANDEMBRY?ANDEMBRY® (garadacimab-gxii) injection, for subcutaneous use, is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in people 12 years and older. It is not known if ANDEMBRY is safe and effective in children under 12 years of age. What should I tell my healthcare provider before using ANDEMBRY?Before using ANDEMBRY, tell your healthcare provider about any medical condition you may have, especially if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if ANDEMBRY can harm your unborn baby or if ANDEMBRY passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while using ANDEMBRY. Tell your healthcare provider about all medications you take, including prescription medicines, over-the-counter treatments, vitamins, and herbal supplements. How should I use ANDEMBRY? Use ANDEMBRY exactly as instructed by your healthcare provider. Detailed instructions for use can be found in the patient information section of the full prescribing information. ANDEMBRY is given as an injection under your skin (subcutaneous) by you or a caregiver. Your healthcare provider should show you or your caregiver how to prepare and inject your dose of ANDEMBRY before you inject yourself for the first time. Do not try to inject ANDEMBRY unless you have been trained by your healthcare provider. What are the possible side effects of ANDEMBRY?The most common side effects of ANDEMBRY include: Redness, itchiness, and bruising (injection-site reactions) Stomach (abdominal) pain Runny or stuffy nose, sneezing, watery eyes (nasopharyngitis) Please see full prescribing information for ANDEMBRY, including patient information and instructions for use. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958. About CSLCSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit Media ContactsValerie BombergerCSLOffice: +1 610-291-5388 Mobile: +1 267-280-3829 Email: Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: Greg HealyCSLMobile: +1 610-906-4564Email: In Australia: Kim O'DonohueCSLMobile: +61 449 884 603Email: Brett FoleyCSLMobile: +61 461 464 708 Email: Investors ContactChris CooperCSLMobile: +61 455 022 740Email:
Associated Press
12-06-2025
- Business
- Associated Press
Pinya XP & True Cut Executives to Host Live on X Discussion on Revolutionary Cannabis Genetic Authentication Partnership
Industry Leaders Will Discuss Breakthrough Blockchain-Based Solution for Cannabis Genetic Verification and IP Protection Pineapple Express Cannabis Company (OTCMKTS:PNXP) 'Authenticate, before you Medicate isn't just a catchphrase—it's our mission. When health is at stake, knowing exactly what you're consuming isn't optional.'— Frank Yglesias-Bertheau ATLANTA, GA, UNITED STATES, June 12, 2025 / / -- Pineapple Express Cannabis Company n/k/a Pinya XP (USOTC: PNXP) and True Cut announce that their executive leadership teams will host a live discussion on X (formerly Twitter) to unveil details of their strategic partnership that is transforming cannabis genetic authentication and intellectual property protection. Event Details: • Platform: Live on X (Twitter Spaces) • Date: June 21st, 2025 • Time: 14:00 EST • Hosts: Brian Worthington, CEO and Founder of True Cut, Frank Yglesias, CEO of PINYA XP, Marc Williams, COO of PINYA XP, & Kevin Jodrey, CCO of PINYA XP What to Expect During this exclusive live session, the executive team will provide in-depth insights into their groundbreaking partnership that integrates True Cut's comprehensive genetic database with Pinya XP's GROOVY 2.0 hyperledger centralized blockchain authentication platform. This collaboration creates the cannabis industry's first end-to-end solution for genetic verification while protecting breeder intellectual property and enhancing consumer trust. Key Discussion Topics Cannabis Industry Transformation • How blockchain technology is revolutionizing genetic authentication • Addressing decades of hybridization challenges and prohibition's impact on genetic diversity • Creating unprecedented transparency in cannabis genetics Breakthrough Technology Integration • Deep dive into GROOVY 2.0 hyperledger blockchain platform capabilities • True Cut's global genetic database and lineage certification process • Real-time demonstration of the integrated authentication system Economic Impact for Industry Stakeholders • Automated royalty systems for original breeders and genetic developers • Protection mechanisms against counterfeit products • Consumer rewards programs driving engagement and verification Future of Cannabis Genomics • Predictive breeding capabilities and effect-based pharmacognosy • AI-powered analytics and genetic intelligence insights • Tools and integrations for operators of every size About True Cut True Cut is the global SaaS based platform to secure cannabis intellectual property and breeding rights. The size and global disposition of the dataset allows True Cut to be an authoritative source of genetic lineage and provides a backbone for predictive breeding and effect based pharmacognosy. We are leading the way in cannabis genomic research and have tools and integrations for operators of every size. About $PNXP Pineapple Express Cannabis Company n/k/a Pinya XP (USOTC: $PNXP) is driven by a mission to save lives through its innovative GROOVY PaaS 4IR Ecosystem. The platform provides unalterable verification of cannabis product authenticity via a centralized Hyperledger Fabric blockchain, creating an immutable seed-to-sale record accessible through QR-NFT tags. This technology prevents counterfeit products from reaching consumers, ensuring product safety and enabling healthcare professionals to recommend products with verified profiles. The company's GROOVY Rewards program transforms authentication into an engaging experience where consumers earn rewards for verifying products and completing educational modules. Its revolutionary Geno-NFT Library provides intellectual property protection for cannabis genetics, enabling growers to register unique strains and receive automatic royalties. Through the GROOVY Marketplace and AI-powered analytics, PINYA XP connects all ecosystem elements to provide actionable business insights while maintaining the highest standards of product safety and quality. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations, assumptions, and projections about future events or financial performance and are not guarantees of future results. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Statements containing words like 'believe,' 'anticipate,' 'endeavor,' 'estimate,' 'expect,' 'project,' 'intend,' or similar expressions identify these forward-looking statements. Specifically, statements regarding future growth, market adoption of Groovy's platform, regulatory developments, technological advancements, and financial performance in the cannabis and cryptocurrency industries are subject to these risks and uncertainties. Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to: the risks associated with the evolving cannabis market, including but not limited to regulatory uncertainties and changes in laws and regulations; competitive pressures within the cannabis sector; technological disruptions impacting operational efficiency; fluctuations in market demand; variations in product pricing; the ability to effectively penetrate new markets; and the potential financial or reputational impacts from legal, administrative, or regulatory developments. Further, risks relating to the volatile nature of the cryptocurrency market, potential security breaches, fluctuations in token values, and changes in investor sentiment are relevant considerations. These factors, as well as risks relating to the general economy, market volatility, and competitive activity, are further detailed within the 'Risk Factors' section of this document. CAUTIONARY STATEMENT REGARDING GROOVY REWARDS TOKENS Groovy Rewards Tokens are digital collectibles designed exclusively for entertainment and community engagement within the Groovy ecosystem. These tokens are explicitly NOT securities or investments under any applicable laws. They represent no ownership stake in any company, confer no voting rights, and provide no entitlement to profits or dividends. Any perceived value exists solely within the Groovy platform. Groovy Rewards Tokens function as digital collectibles similar to virtual trading cards or digital art, existing only to enhance user experiences and build community engagement. They possess none of the defining characteristics of securities: they confer no ownership rights or equity; holders receive no profit-sharing or revenue distributions; the tokens grant no control over business operations; and any value fluctuations are disconnected from company performance. Users must understand these tokens possess no intrinsic monetary value; they're not backed by tangible assets; no promises or guarantees regarding future utility are made; their perceived value may experience extreme volatility; and regulatory changes could impact their functionality or existence. These tokens should ONLY be acquired for legitimate non-financial purposes: entertainment within the Groovy ecosystem; participation in community activities; exploration of blockchain technology; and expression of brand appreciation—never with any expectation of profit or as an investment. By acquiring or using Groovy Rewards Tokens, participants acknowledge they understand these are non-financial digital collectibles with no investment characteristics; have no profit expectations from company activities; accept all associated risks including potential complete loss of utility; will use tokens exclusively for entertainment purposes; and comply with all applicable regulations regarding digital collectibles. Franjose Yglesias Pineapple Express Cannabis Company [email protected] Visit us on social media: LinkedIn X Other Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
11-06-2025
- Business
- Associated Press
Pinya XP and True Cut Announce Strategic Partnership to Transform Cannabis Genetic Authentication
Collaboration combines blockchain authentication with genetic verification to create industry's first consumer trust and royalty distribution platform Pineapple Express Cannabis Company (OTCMKTS:PNXP) 'Authenticate, before you Medicate isn't just a catchphrase—it's our mission. When health is at stake, knowing exactly what you're consuming isn't optional.'— Frank Yglesias-Bertheau ATLANTA, GA, UNITED STATES, June 11, 2025 / / -- Pineapple Express Cannabis Company n/k/a Pinya XP (USOTC: PNXP), a leader in Platform as a Service (PaaS) in a centralized Hyperledger blockchain-based cannabis authentication solutions, and True Cut, a pioneering Software as a Service (SaaS)-based global data provider for cannabis genetics, today announced a strategic partnership to revolutionize cannabis genetic verification, intellectual property protection, and consumer trust. The partnership will integrate True Cut's comprehensive genetic database with Pinya XP's GROOVY 2.0 hyperledger centralized blockchain authentication platform, creating an end-to-end solution that verifies product authenticity while protecting genetic intellectual property and rewarding consumers for participation. 'This collaboration represents a watershed moment for cannabis genetic authentication and transparency,' said Kevin Jodrey, CCO of Pinya XP. 'By combining our blockchain authentication technology with True Cut's genetic expertise, we're creating a system that not only protects consumers from counterfeit products but also ensures that the breeders who developed these genetics receive proper recognition and compensation.' The partnership addresses critical challenges in the cannabis industry stemming from decades of hybridization and the destructive efforts of prohibition, which have raised significant concerns about genetic diversity, intellectual property protection, and consumer confidence. 'After years of extensive cannabis population studies and lineage certifications, we're thrilled to integrate our genetic database with Pinya XP's blockchain platform,' said Brian Worthington, CEO and Founder of True Cut. 'This partnership enables us to provide growers, breeders, and consumers with unprecedented genetic observability while ensuring original breeders receive automated royalties whenever their genetics are authenticated.' 'We're not just authenticating products—we're creating the industry's most comprehensive genetic intelligence platform,' added Frank Yglesias CEO of PINYA XP. 'The insights generated through this partnership will drive innovation, improve product development, and ultimately enhance the consumer experience.' About True Cut True Cut is the global SaaS based platform to secure cannabis intellectual property and breeding rights. The size and global disposition of the dataset allows True Cut to be an authoritative source of genetic lineage and provides a backbone for predictive breeding and effect based pharmacognosy. We are leading the way in cannabis genomic research and have tools and integrations for operators of every size. About $PNXP Pineapple Express Cannabis Company n/k/a Pinya XP (USOTC: $PNXP) is driven by a mission to save lives through its innovative GROOVY PaaS 4IR Ecosystem. The platform provides unalterable verification of cannabis product authenticity via a centralized Hyperledger Fabric blockchain, creating an immutable seed-to-sale record accessible through QR-NFT tags. This technology prevents counterfeit products from reaching consumers, ensuring product safety and enabling healthcare professionals to recommend products with verified profiles. The company's GROOVY Rewards program transforms authentication into an engaging experience where consumers earn rewards for verifying products and completing educational modules. Its revolutionary Geno-NFT Library provides intellectual property protection for cannabis genetics, enabling growers to register unique strains and receive automatic royalties. Through the GROOVY Marketplace and AI-powered analytics, PINYA XP connects all ecosystem elements to provide actionable business insights while maintaining the highest standards of product safety and quality. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations, assumptions, and projections about future events or financial performance and are not guarantees of future results. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Statements containing words like 'believe,' 'anticipate,' 'endeavor,' 'estimate,' 'expect,' 'project,' 'intend,' or similar expressions identify these forward-looking statements. Specifically, statements regarding future growth, market adoption of Groovy's platform, regulatory developments, technological advancements, and financial performance in the cannabis and cryptocurrency industries are subject to these risks and uncertainties. Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to: the risks associated with the evolving cannabis market, including but not limited to regulatory uncertainties and changes in laws and regulations; competitive pressures within the cannabis sector; technological disruptions impacting operational efficiency; fluctuations in market demand; variations in product pricing; the ability to effectively penetrate new markets; and the potential financial or reputational impacts from legal, administrative, or regulatory developments. Further, risks relating to the volatile nature of the cryptocurrency market, potential security breaches, fluctuations in token values, and changes in investor sentiment are relevant considerations. These factors, as well as risks relating to the general economy, market volatility, and competitive activity, are further detailed within the 'Risk Factors' section of this document. CAUTIONARY STATEMENT REGARDING GROOVY REWARDS TOKENS Groovy Rewards Tokens are digital collectibles designed exclusively for entertainment and community engagement within the Groovy ecosystem. These tokens are explicitly NOT securities or investments under any applicable laws. They represent no ownership stake in any company, confer no voting rights, and provide no entitlement to profits or dividends. Any perceived value exists solely within the Groovy platform. Groovy Rewards Tokens function as digital collectibles similar to virtual trading cards or digital art, existing only to enhance user experiences and build community engagement. They possess none of the defining characteristics of securities: they confer no ownership rights or equity; holders receive no profit-sharing or revenue distributions; the tokens grant no control over business operations; and any value fluctuations are disconnected from company performance. Users must understand these tokens possess no intrinsic monetary value; they're not backed by tangible assets; no promises or guarantees regarding future utility are made; their perceived value may experience extreme volatility; and regulatory changes could impact their functionality or existence. These tokens should ONLY be acquired for legitimate non-financial purposes: entertainment within the Groovy ecosystem; participation in community activities; exploration of blockchain technology; and expression of brand appreciation—never with any expectation of profit or as an investment. By acquiring or using Groovy Rewards Tokens, participants acknowledge they understand these are non-financial digital collectibles with no investment characteristics; have no profit expectations from company activities; accept all associated risks including potential complete loss of utility; will use tokens exclusively for entertainment purposes; and comply with all applicable regulations regarding digital collectibles. Franjose Yglesias Pineapple Express Cannabis Company [email protected] Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
11-03-2025
- Business
- Associated Press
Pineapple Express Cannabis Company and Groovy Company Announce Strategic Share Exchange Agreement
Strategic acquisition combines GROOVY's blockchain-based cannabis authentication platform with Pineapple Express's industry presence ATLANTA, GA / ACCESS Newswire / March 11, 2025 / Pineapple Express Cannabis Company d/b/a PINYA XP (OTC PINK:PNXP) and GROOVY Company, Inc. f/k/a Santo Mining Corp. (USOTC:SANP) today announced the execution of a Share Exchange Agreement, creating a powerful partnership in the cannabis technology and authentication XP Under the terms of the agreement, Pineapple Express Cannabis Company will acquire a controlling interest in GROOVY Company, making GROOVY a subsidiary of Pineapple Express. The transaction will be executed through an exchange of 350,000,000 shares of Series A Preferred shares of GROOVY for 5,000,000 shares of common stock of Pineapple Express. This strategic combination leverages GROOVY's innovative centralized Hyperledger blockchain-based Platform as a Service (PaaS) with Pineapple Express's established position in the cannabis industry. 'This partnership represents a significant milestone in our mission to bring transparency and trust to the cannabis industry,' said Frank Yglesias, who serves as CEO of both companies. 'By combining GROOVY's cutting-edge blockchain authentication technology with Pineapple Express's industry presence, we're positioned to revolutionize how consumers verify the authenticity and origin of cannabis products.' About GROOVY's NFT-QR Tag Authentication System GROOVY has developed a pioneering platform that leverages Hyperledger Fabric blockchain technology and NFT standards (ERC1155, ERC725X, ERC725Y, and ERC735) to address significant challenges in the cannabis industry. The platform utilizes NFT-based QR codes to verify the authenticity and origin of cannabis products, combating counterfeiting and providing consumers with verifiable information. Key features of the platform include: Strategic Benefits This transaction provides several strategic advantages: The transaction is expected to close in the coming weeks, subject to customary closing conditions. About PINYA XP fna Pineapple Express Cannabis Company dba PINYA XP At PINYA XP (USOTC:PNXP), our mission begins with saving lives. Through our GROOVY PaaS 4IR Ecosystem, we provide unalterable verification of cannabis product authenticity, ensuring consumers receive exactly what they expect. This blockchain-powered system prevents counterfeit products from reaching the market, protecting consumers from potentially harmful substances while enabling healthcare professionals to confidently recommend products with verified profiles. Our centralized Hyperledger Fabric blockchain creates an immutable record of each product's journey from seed to sale. Every scan of our QR-NFT tags reveals a complete history of the product's cultivation, testing, and distribution, establishing an unbreakable chain of trust throughout the supply chain. This transparency isn't just about compliance - it's about creating a safer cannabis industry for everyone. The GROOVY Rewards program transforms product authentication into an engaging experience. Consumers earn rewards for verifying products, completing educational modules, and participating in our community. This gamification approach not only encourages active participation in product safety but also generates valuable data insights that help drive industry improvements. Our Geno-NFT Library revolutionizes intellectual property protection in cannabis. This secure, blockchain-based repository allows growers to register their unique strains and receive automatic royalties when their genetics are used in authenticated products. By ensuring fair compensation for innovation, we're fostering the development of new, high-quality cannabis varieties. The GROOVY Marketplace connects all these elements into a comprehensive ecosystem where authenticated products, verified genetics, and engaged consumers come together. Our AI-powered analytics engine processes this rich data to provide actionable insights, enabling businesses to make informed decisions while ensuring product safety and quality. Cautionary Statement Regarding Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations, assumptions, and projections about future events or financial performance and are not guarantees of future results. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Statements containing words like 'believe,' 'anticipate,' 'endeavor,' 'estimate,' 'expect,' 'project,' 'intend,' or similar expressions identify these forward-looking statements. Specifically, statements regarding future growth, market adoption of Groovy's platform, regulatory developments, technological advancements, and financial performance in the cannabis and cryptocurrency industries are subject to these risks and uncertainties. Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to: the risks associated with the evolving cannabis market, including but not limited to regulatory uncertainties and changes in laws and regulations; competitive pressures within the cannabis sector; technological disruptions impacting operational efficiency; fluctuations in market demand; variations in product pricing; the ability to effectively penetrate new markets; and the potential financial or reputational impacts from legal, administrative, or regulatory developments. Further, risks relating to the volatile nature of the cryptocurrency market, potential security breaches, fluctuations in token values, and changes in investor sentiment are relevant considerations. These factors, as well as risks relating to the general economy, market volatility, and competitive activity, are further detailed within the 'Risk Factors' section of this document. The Company does not undertake any obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events, or otherwise. Investors should carefully consider these factors and the risks discussed throughout this report before making any investment decisions. This statement is made for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Further, investors should independently research and evaluate the potential risks and rewards of investing in the Company and the cannabis and cryptocurrency sectors. CEO
Associated Press
04-03-2025
- Business
- Associated Press
Pinya XP Fka Pineapple Express Cannabis Company Announces New Corporate Image
PINYA XP Unveils Digital Hub for Cannabis Authentication Technology with Integrated Resources for Partners, Developers, and Industry Stakeholders ATLANTA, GEORGIA / ACCESS Newswire / March 4, 2025 / Pinya XP aka Pineapple Express Cannabis Company (USOTC:PNXP) ('PINYA XP' or the 'Company'), a leader in cannabis authentication and verification technology, today announced the launch of its new corporate website at designed to showcase the Company's innovative GROOVY PaaS 4IR Ecosystem. The new website features a comprehensive overview of the Company's blockchain-based authentication technology, detailed product information, and educational resources for various stakeholders in the cannabis supply chain. The modern, user-friendly design reflects PINYA XP's commitment to innovation and transparency in the cannabis industry. 'Our new website serves as a digital hub for our vision of creating a safer, more transparent cannabis industry,' said Franjose 'Frank' Yglesias, CEO of PINYA XP. 'We've designed it to provide clear, accessible information about our GROOVY platform and how our blockchain verification technology protects consumers, growers, manufacturers, and retailers. The site embodies our mission and showcases the cutting-edge solutions we're bringing to market.' Key features of the new website include: News and media center for company announcements In addition to the main corporate site, PINYA XP has launched two complementary digital resources: PINYA Wiki ( A comprehensive knowledge base providing detailed technical documentation, implementation guides, and best practices for partners and developers working with the GROOVY platform. The Wiki serves as an educational resource for understanding cannabis authentication technology and blockchain applications in the industry. PINYA News ( A dedicated news portal covering the latest developments in cannabis authentication, blockchain verification, and industry regulations. The site features company announcements, case studies, market insights, and thought leadership content from PINYA XP's executive team. The website will also introduces the GROOVY mobile application, which allows consumers to verify the authenticity of cannabis products by scanning QR-NFT tags. Through this application, users can access complete product information, including strain details, lab results, and cultivation data, while earning rewards for verified scans. 'We've created a digital experience that matches the sophistication of our technology platform,' added Marc Williams, Chief Operations Officer. 'The new website, along with our Wiki and News resources, clearly communicates how our authentication ecosystem functions from seed to sale, providing value to every participant in the cannabis supply chain.' The website launch coincides with the Company's recent leadership transition and strategic relocation to Atlanta, Georgia, positioning PINYA XP at the forefront of cannabis authentication technology innovation. To explore the new website and learn more about PINYA XP's authentication solutions, visit About Pineapple Express Cannabis Company dba PINYA XP At PINYA XP (USOTC:PNXP), our mission begins with saving lives. Through our GROOVY PaaS 4IR Ecosystem, we provide unalterable verification of cannabis product authenticity, ensuring consumers receive exactly what they expect. This blockchain-powered system prevents counterfeit products from reaching the market, protecting consumers from potentially harmful substances while enabling healthcare professionals to confidently recommend products with verified profiles. Our centralized Hyperledger Fabric blockchain creates an immutable record of each product's journey from seed to sale. Every scan of our QR-NFT tags reveals a complete history of the product's cultivation, testing, and distribution, establishing an unbreakable chain of trust throughout the supply chain. This transparency isn't just about compliance - it's about creating a safer cannabis industry for everyone. The GROOVY Rewards program transforms product authentication into an engaging experience. Consumers earn rewards for verifying products, completing educational modules, and participating in our community. This gamification approach not only encourages active participation in product safety but also generates valuable data insights that help drive industry improvements. Our Geno-NFT Library revolutionizes intellectual property protection in cannabis. This secure, blockchain-based repository allows growers to register their unique strains and receive automatic royalties when their genetics are used in authenticated products. By ensuring fair compensation for innovation, we're fostering the development of new, high-quality cannabis varieties. The GROOVY Marketplace connects all these elements into a comprehensive ecosystem where authenticated products, verified genetics, and engaged consumers come together. Our AI-powered analytics engine processes this rich data to provide actionable insights, enabling businesses to make informed decisions while ensuring product safety and quality. Cautionary Statement Regarding Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations, assumptions, and projections about future events or financial performance and are not guarantees of future results. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Statements containing words like 'believe,' 'anticipate,' 'endeavor,' 'estimate,' 'expect,' 'project,' 'intend,' or similar expressions identify these forward-looking statements. Specifically, statements regarding future growth, market adoption of Groovy's platform, regulatory developments, technological advancements, and financial performance in the cannabis and cryptocurrency industries are subject to these risks and uncertainties. Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to: the risks associated with the evolving cannabis market, including but not limited to regulatory uncertainties and changes in laws and regulations; competitive pressures within the cannabis sector; technological disruptions impacting operational efficiency; fluctuations in market demand; variations in product pricing; the ability to effectively penetrate new markets; and the potential financial or reputational impacts from legal, administrative, or regulatory developments. Further, risks relating to the volatile nature of the cryptocurrency market, potential security breaches, fluctuations in token values, and changes in investor sentiment are relevant considerations. These factors, as well as risks relating to the general economy, market volatility, and competitive activity, are further detailed within the 'Risk Factors' section of this document. The Company does not undertake any obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events, or otherwise. Investors should carefully consider these factors and the risks discussed throughout this report before making any investment decisions. This statement is made for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Further, investors should independently research and evaluate the potential risks and rewards of investing in the Company and the cannabis and cryptocurrency sectors. 4047343277
